For patients with chronic myeloid leukaemia, methods for monitoring response to treatment
have changed considerably in recent years. In the 1980s, the principal approach was …

The principle aim of residual disease analysis in patients with chronic myeloid leukaemia
(CML) is to gauge patient response to treatment and, in patients after allogeneic BMT, to …

PURPOSE Disappearance of the Philadelphia chromosome during treatment for chronic
myeloid leukemia (CML) has become an important therapeutic end point. To determine the …

There is a need for fast and sensitive methods to evaluate the response of patients with
chronic myeloid leukaemia (CML) to interferon‐α (IFN‐α) therapy to complement cytogenetic …

About 75% of patients with newly diagnosed chronic phase (CP) chronic myeloid leukemia
(CML) treated initially with imatinib achieve complete cytogenetic remission (CCyR), 1 and …

To test whether patients in remission after allogeneic bone marrow transplantation (BMT)
possess a pool of chronic myeloid leukemia (CML) cells that do not express BCR-ABL …

The degree of tumor load reduction after therapy, which is determined by the degrees of
cytoreduction and cytogenetic response, is an important prognostic factor for patients with …

The degree of tumor load reduction after therapy is an important prognostic factor for
patients with CML. Conventional metaphase analysis has been considered to be the 'gold …

Chronic myeloid leukemia (CML) is a clonal myeloproliferative disease caused by
recombination between the BCR gene on chromosome 22 and the ABL1 gene on …

We identified 103 consecutive patients who, 5 years after allogeneic transplantation for
chronic myeloid leukaemia (CML), were in molecular remission (MR). The 103 patients were …